Analysis for JNJ

📈 Growth & Financial Trajectory

Across the available 7 quarters, revenues rose from $22.52B (2024 Q3) to $25.31B (2026 Q2), a ~12% increase. Net income climbed from $2.69B to $5.53B, up ~105%, signaling improved profitability as gross margins held in the high-60s to around 70%. Operating income rose from roughly $3.86B to $6.75B, with margins in the mid‑20s to low‑30s, and consistent quarterly improvement.

💰 Margins & Cash Flow

• Gross Margin remains strong, around 67-70% across quarters.
• Operating Margin generally in the mid‑20s to low‑30s, reflecting solid operating leverage.
• Net cash flow from operating activities is positive in most quarters, with cash on hand ranging roughly from $20B to $39B, and investing/financing activity causing occasional swings in free cash flow.

🛡️ Balance Sheet & Liquidity

Assets run roughly $180–$201B with liabilities around $113–$119B and equity historically in the $70–85B range. Cash sits in the $20–$40B band, and liquidity remains ample despite sizable noncurrent liabilities and debt load. The balance sheet shows durable equity and ample asset base to absorb changes in operating performance.

⚠️ Key Drivers & Risks

• Drivers: Diversified healthcare portfolio (pharma, devices, consumer) and resilient demand with pricing power.
• Risks: Regulatory pressure and litigation exposure; policy/currency shifts and valuation sensitivity in healthcare.